Eledon Pharmaceuticals Management
Management criteria checks 2/4
Eledon Pharmaceuticals' CEO is DA Gros, appointed in Sep 2020, has a tenure of 3.67 years. total yearly compensation is $2.55M, comprised of 21.9% salary and 78.1% bonuses, including company stock and options. directly owns 0.036% of the company’s shares, worth $21.96K. The average tenure of the management team and the board of directors is 3.1 years and 5.4 years respectively.
Key information
DA Gros
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 21.9% |
| CEO tenure | 3.7yrs |
| CEO ownership | 0.04% |
| Management average tenure | 3.1yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Mar 22
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Dec 05Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?
Aug 10We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Apr 27Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation
Jan 05Eledon adds 10% as FDA clears clinical trial for kidney disease candidate
Sep 06Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?
Aug 31Eledon gets FDA nod to start trial of organ rejection preventing therapy
Aug 01Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients
Jul 18Eledon gives update on development strategy for AT-1501 in renal transplantation
Apr 26Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans
Apr 14What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?
Feb 21Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation
Dec 30
Novus Therapeutics (NVUS) Investor Presentation - Slideshow
Dec 18Novus Therapeutics EPS misses by $3.76
Nov 16Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease
Nov 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$559k | -US$40m |
| Sep 30 2023 | n/a | n/a | -US$89m |
| Jun 30 2023 | n/a | n/a | -US$89m |
| Mar 31 2023 | n/a | n/a | -US$89m |
| Dec 31 2022 | US$1m | US$533k | -US$88m |
| Sep 30 2022 | n/a | n/a | -US$38m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$36m |
| Dec 31 2021 | US$748k | US$504k | -US$35m |
| Sep 30 2021 | n/a | n/a | -US$32m |
| Jun 30 2021 | n/a | n/a | -US$28m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$7m | US$150k | -US$23m |
Compensation vs Market: DA's total compensation ($USD2.55M) is above average for companies of similar size in the US market ($USD661.60K).
Compensation vs Earnings: DA's compensation has increased whilst the company is unprofitable.
CEO
DA Gros (51 yo)
3.7yrs
Tenure
US$2,553,153
Compensation
Dr. David-Alexandre C. Gros, also known as DA, M.D., Ph D., serves as Chief Executive Officer and Non-Independent Director at Eledon Pharmaceuticals, Inc. since September 09, 2020. He served as Executive O...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Non Independent Director | 3.7yrs | US$2.55m | 0.036% $ 22.0k | |
| President | 3.7yrs | US$1.54m | 0.0040% $ 2.4k | |
| CFO & Principal Accounting Officer | 3.2yrs | US$1.32m | 0.040% $ 24.4k | |
| Vice President of Technical Operations | 2yrs | no data | no data | |
| General Counsel | 3.1yrs | US$1.68m | 0% $ 0 | |
| Chief Regulatory Officer | 3.1yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
3.1yrs
Average Tenure
54yo
Average Age
Experienced Management: ELDN's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Non Independent Director | 3.7yrs | US$2.55m | 0.036% $ 22.0k | |
| President | 3.7yrs | US$1.54m | 0.0040% $ 2.4k | |
| Independent Chairman of the Board | 7yrs | US$1.52m | 0.0027% $ 1.7k | |
| Independent Director | 3.7yrs | US$371.82k | 0% $ 0 | |
| Independent Director | 7yrs | US$371.82k | 0% $ 0 | |
| Independent Director | less than a year | US$201.79k | no data | |
| Member of Scientific Advisory Board | 5.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.4yrs | no data | no data |
5.4yrs
Average Tenure
55yo
Average Age
Experienced Board: ELDN's board of directors are considered experienced (5.4 years average tenure).